Results 131 to 140 of about 3,026 (236)

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Warning as to Use of Hay-Fever Toxin [PDF]

, 1914
R. C. Lowdermilk
openalex   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

ON THE IMMUNIZATION TREATMENT OF HAY FEVER. [PDF]

, 1902
E. FLETCHER INGALS
openalex   +1 more source

A novel treatment of biogas digestate waste for biochar production and its adsorption of methylene blue and malachite green in a binary system

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study presents a novel treatment of biogas digestate to produce biochar at processing temperatures of 500–700 °C. The resulting biochar was applied for the simultaneous removal of methylene blue (MB) and malachite green (MG) in a binary system.
Van Hau Duong, Pham Xuan Phuong, Phan Thi Duy Thuan, Altyn Taisheva, Dinh Van Dung, Le Dinh Phung, Nguyen Thi Hong Bich, Nguyen Duy Luu, Dinh Quang Khieu, Filip Mercl, Hynek Roubík   +10 more
wiley   +1 more source

Art. XXII.—Autumnal Catarrh (Hay Fever). With three Maps. [PDF]

, 1872
Morrill Wyman
openalex   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

This year's experience with the treatment of hay fever for stay‐at‐homes [PDF]

, 1899
Scheppegrell
openalex   +1 more source

EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding

British Journal of Clinical Pharmacology, EarlyView.
Aims We aimed to describe suspected adverse drug reactions (ADRs) in infants resulting from medications transmitted through mothers' milk, as reported to the European ADR database, EudraVigilance. The research sought to understand the frequency, seriousness and nature of these ADRs to assess potential risks associated with maternal medication use ...
Ida M. Heerfordt, Ditte Resendal Gotfredsen, Henrik Horwitz, Anette Kirstine Stark, Jon Trærup Andersen, Christina Gade, Ulrik Lausten‐Thomsen, Rasmus Huan Olsen   +7 more
wiley   +1 more source

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan, Daan J. Touw, Marjolijn N. Lub‐de Hooge, Thijs H. Oude Munnink   +3 more
wiley   +1 more source